2-Bromotoluene | CAS:95-46-5

We serve 2-Bromotoluene CAS:95-46-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromotoluene

Chemical Name:   2-Bromotoluene
CAS.NO:95-46-5
Synonyms:   2-Bromotoluene
toluene,2-bromo
ortho-bromotoluene
2-bromo-1-methylbenzene
Benzene, 1-bromo-2-methyl-
O-BROMOTOLUENE
 
Molecular Formula:C7H7Br
Molecular Weight:171.03400
 
Physical and Chemical Properties:
Density:1.422 g/mL at 25 °C(lit.)
Boiling point:58-60 °C10 mm Hg(lit.)
Melting point:-27 °C
Flash point:174 °F
Index of Refraction:1.555
 
Specification:
Appearance:Liquid
Purity:≥99.0%
 
Packing:25kg/drum, can also be packaged according to customer requirements
Storage:The warehouse is ventilated and dried at low temperature, and stored and transported separately from oxidants and food materials.
Application:It is used in organic synthesis and as a solvent.



Contact us for information like 2-Bromotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,O-BROMOTOLUENE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromotoluene Use and application,2-Bromotoluene technical grade,usp/ep/jp grade.


Related News: Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.6-Carboxy-4-methyl-2-propylbenzimidazole manufacturer A new case of coronavirus has been reported in the United Arab Emirates, the country’s fifth, the Ministry of Health and Prevention announced on Saturday.N-(1,3-Dihydro-1,3-dioxoisobenzofuran-4-yl)acetamide supplier Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.(2-butyl-5-nitro-1-benzofuran-3-yl)-(4-methoxyphenyl)methanone vendor Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).